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A rapid, but sensitive and selective method for confirmation and quantitation of benzoylecgo-
nine (BZE) and cocaine (COC) in urine by fast-gradient liquid chromatography/tandem mass
spectrometry (LC/MS/MS) is described. The chromatographic separation was performed on
a reversed phase column employing fast-gradient techniques. Matrix prepared standards,
blanks, and QC’s were filtered then aliquots were transferred into a 96 well plate. Injection
volumes of 25 mL were made onto the analytical column, with the flow diverted from the
atmospheric pressure ionization source for the first 0.5 min of the analysis. Simultaneous
multiple reaction monitoring (MRM) of three discrete transitions for each compound were
used to identify BZE and COC. Quantitation was achieved utilizing the most prominent
parent–daughter transition and internal standard calibration techniques. The coefficients of
variation (CV) for the analysis of these drugs ranged from 0.6% to 6.8% at a concentration of
150 ng/mL (n 5 155). This method suggests that fast-gradient LC/MS/MS may be suitable
for routine confirmation of immunoassay cocaine-positive samples. (J Am Soc Mass Spec-
trom 2000, 11, 257–263) © 2000 American Society for Mass Spectrometry
Benzoylecgonine (BZE), a demethylation productof cocaine (COC) and the major metabolite foundin humans, does not exhibit any pharmacological
activity. It has wide toxicological interest however, due
to its long half-life, and remains detectable in biological
fluids considerably longer than COC. Increased public
awareness and widespread abuse of COC and “crack”
have resulted in more frequent urinalysis screening.
Rapid and sensitive immunoassay methods such as
Emit and TDx [1, 2] are commonly employed to screen
urine specimens for COC and metabolites (CACM).
Positive screening tests are routinely confirmed by gas
chromatography/mass spectrometry (GC/MS) [3, 4].
Thermal lability of polar COC metabolites necessitates
derivatization to an appropriate analog prior to analysis
by GC/MS. This can be a complicated and time-inten-
sive process.
These methods may also lead to erroneous interpre-
tations of CACM concentrations in biological matrices.
For example, falsely high results are obtained for meth-
ylation procedures used to convert BZE to COC, if
original cocaine quantities are not accounted for. Con-
versely, simultaneous use of ethanol and COC may
form BZE endogenously [5]. Therefore, methods used
to ethylate BZE to ethylcocaine may also produce
inaccurate results.
Separations of polar compounds have been com-
monly performed by high performance liquid chroma-
tography (HPLC) without the need for chemical deri-
vatization [6, 7]. Although HPLC is widely used as a
separation technique for CACM analyses, sensitivity
issues arising from weakly absorbing UV chro-
mophores may render UV detection impractical.
LC/MS has gained popularity as an analytical tool for
the separation and detection of polar, nonvolatile, and
thermally labile compounds without prior derivatiza-
tion [8–10].
Furthermore, LC/MS coupled with electrospray ion-
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ization (ESI) and/or atmospheric pressure chemical
ionization (APCI) tandem mass spectrometry (MS/MS)
has gained increased acceptance for confirmatory and
quantitative analysis of drugs in biological fluids [11,
12]. Although ESI tandem mass spectrometry provides
excellent selectivity, and sensitivity, the direct injection
of urine onto an analytical column has been thought to
be problematic. Endogenous material in the urine ma-
trix can degrade chromatographic performance, cause
fouling of the atmospheric pressure ionization source,
and lead to ionization suppression of the desired ana-
lytes during the ion evaporation process [13]. During
ion evaporation, urinary constituents (urea, uric acid,




ucts and other endogenous compounds dramatically
reduce sensitivity and reproducibility of the assay.
Therefore, to preclude ionization suppression effects,
urine specimens may require cleanup or salt diversion
prior to analysis.
Consequently, we have designed a “simplified” LC/
MS/MS assay for rapid and simultaneous determina-
tion of BZE and COC in human urine. After initially
filtering the specimen, additional sample pretreatment
steps are not required. This method affords increased
selectivity, sensitivity, reproducibility, and throughput
over previously described methods [14–16].
Materials and Methods
Chemicals and Reagents
Cocaine (free base), benzoylecgonine hydrate, and co-
caine-d3 were obtained from SIGMA Chemical (St.
Louis, MO). A weighing of each analyte was made in
duplicate from neat material and standard stock solu-
tions (300,000 ng/mL) of these compounds were pre-
pared in HPLC grade methanol obtained from J. T.
Baker (Phillipsburgh, NJ) and stored at 4 °C. Primary
Figure 1. Electrospray positive ion product mass spectra acquired at a collision cell gas pressure of
2.2 mtorr and collision energies varying from 29 to 69 eV, and the proposed dissociation pathways for
benzoylecgonine ([M 1 H]1 m/z of 290.0) (a), cocaine ([M 1 H]1 m/z of 304.2) (b), and cocaine-d3
([M 1 H]1 m/z of 307.2) (c).
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dilutions of the standard stock solutions were made to
provide secondary stocks (1000 ng/mL) in a 50:50
mixture of HPLC grade H2O and HPLC grade acetoni-
trile, also obtained from J. T. Baker. Working standards
were prepared by appropriate dilution of the secondary
stock standards into “pooled” urine. Aliquots of the
BZE and COC working standards were combined into a
single set, and diluted individually to eight different
concentrations (7.5, 15, 30, 75, 150, 500, and 1000 ng/
mL). A standard stock COC-d3 solution was prepared at
a concentration of 191 ng/mL in DMSO. A dilution of
this standard solution was made into a 50:50 mixture of
HPLC grade H2O and HPLC grade acetonitrile to give
a working concentration of 1000 ng/mL. All specimens
were spiked with 13 mL of this internal standard before
filtering to give a working concentration of 150 ng/mL.
BZE and COC quality control specimens were prepared
using “blank-pooled” urine and the duplicate standard
solution at 30, 150, and 1000 ng/mL concentrations. All
solutions were filtered through a 0.22 mm MILLEX-GV
filter unit, obtained from MILLIPORE (Bedford, MA).
The aqueous component of the mobile phase was
adjusted to pH 4.0 with analytical grade formic acid
obtained from Acros (Geel, Belgium) and ammonium
hydroxide obtained from J. T. Baker. All LC/MS/MS
mobile phases were filtered through a 0.45 mm TF
(PTFE) membrane filter, Gelman Sciences (Ann Arbor,
MI).
Sample Preparation
Urine specimens were amassed from volunteers (20
female: 20 male, ages 23–46) at Pfizer Central Research
(Groton, Connecticut). The specimens were collected in
50-mL FALCON polypropylene centrifuge tubes from
Becton Dickinson. Aliquots of urine specimens were
taken with a sterile, disposable 10-mL polypropylene
syringe, Becton Dickinson (Franklin Lakes, NJ) and
transferred to a 15-mL borosilicate, disposable snap-cap
centrifuge tubes, Kimble Glass (Chicago, Illinois). Urine
aliquots, QC, and standard curves were transferred into
96 deep well plates, Marsh Biomedical Products (Roch-
ester, NY) prior to analysis.
Apparatus
The analytical instrumentation used consisted of an
API-2000 Beta version, triple quadrupole mass spectrom-
eter, PE-SCIEX (Ontario, Canada), CTC PAL Prep and
Load System Autosampler, LEAP Technologies
Figure 2. MSn experiments conducted on an ion trap mass spectrometer at 15% collision energy and
isolation width of 2.0 u to confirm the postulated decomposition of COC-d3 to ecgonidine methyl-
ester-d3 (m/z 185.1), ecgonidine aldehyde-d3 (m/z 153.0), and methylpyrrole-d3 (m/z 85.0) moieties.
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(Carrboro, NC), (2) Jasco HPLC Pumps model PU-980
and Jasco HPLC Degasser model DG-980-50, JASCO
(Tokyo, Japan), VICI Model E36 10-port column switch-
ing valve, Valco Instruments (Houston, TX), a Power
Macintosh Model 8600/300, Apple Computer (Cuper-
tino, CA), and data acquisition/processing system op-
erating Mass Chrom 1.1b5 software, PE-SCIEX (Ontar-
io, Canada). Chromatography was performed on a
2.0-mm i.d. 3 50-mm with 5.0 mm packing, Advantage
Basic column, Analytical Sales and Service (Mahwah,
NJ).
Analytical Procedure
The pH of the individual urine specimens was mea-
sured, and filtered 1.0 mL aliquots were transferred to
50-mL centrifuge tubes and thoroughly mixed to form a
“pooled” sample. 1 mL of the pooled urine was then
added to each in a series of borosilicate centrifuge tubes
for preparation of the standard curves, blanks, and QC.
Afterwards, 300 mL of each standard, blank, and QC
was transferred to a clean, 96-deep well plate. Mobile
phase conditions were as follows: 90% pH 4.0 HPLC
Grade H2O: 10% HPLC Grade acetonitrile at a flow rate
of 0.6 mL/min for 0.5 min. During this initial period,
the switching valve was in the divert position, averting
presentation of unwanted endogenous material to the
ion source. At 0.51 min, the valve was switched in-line
with the API ion source. The mobile phase was ballis-
tically ramped to 10% pH 4.0 HPLC Grade H2O: 90%
HPLC Grade acetonitrile at 1.0 min, and held for 1.0
min. At 2.1 min, the switching valve was reset and the
gradient was stepped-down to initial conditions. 25 mL
volumes of urine were injected into the LC/MS/MS
system. The output of the HPLC column flowed into the
electrospray interface of the mass spectrometer. The
interface was operated at a turboionspray temperature
of 150 °C and in the positive ion mode for all acquisi-
tions. Conditions for Q1 scans and MRM transitions
were: ESI electrode voltage of 5500, nebulizer gas pres-
sure at 25 lb/in.2, turboionspray gas pressure at 12
lb/in.2, and curtain gas pressure at 45 lb/in.2 Collision-
induced dissociation (CID) studies were performed
using nitrogen with a collision cell gas pressure of 2.2
mtorr and collision energies varying from 29 to 69 eV,
depending on the discrete MRM. The CEM was oper-
ated at 2325 V, and the dwell time for each transition
was 15 ms. MRM transitions monitored for BZE: 290.2
m/z 3 168.2 m/z (quantitation), 290.2 m/z 3 105.2 m/z
(qualifying), 290.2 m/z3 77.2 m/z (qualifying), for COC:
304.2 m/z 3 182.0 m/z (quantitation), 304.2 m/z 3 105.0
m/z (qualifying), 304.2 m/z 3 82.1 m/z (qualifying), and
for cocaine-d3 (Internal Standard): 307.2 m/z3 185.2 m/z
(quantitation), 307.2 m/z3 104.9 m/z (qualifying), 307.2
m/z3 85.1 m/z (qualifying). For the mechanistic decom-
position studies utilizing COC-d3, a Finnigan LCQ ion
trap mass spectrometer was used in the positive ion ESI
mode. The spray voltage was ;2.4 kV with a current of
about 20 mA. The sheath and auxiliary gases were set at
80 and 120 arbitrary units, respectively. The capillary
unit was maintained at an offset of 3.3 V and 200 °C.
The ionization time was set to 200 ms, and three
Figure 3. Proposed mechanistic decomposition of cocaine to ecgonidine methyl ester and ecgonidine
aldehyde at m/z 182.0 and 150.0, respectively.
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microscans were collected for each data point. MSn
studies were conducted at 15% collision energy with a
target isolation width of 2 u.
Chromatography
We selected the 2.0-mm i.d. 3 50-mm with 5.0 mm
packing, Advantage Basic column. This reverse-phase
C-8 column is highly end capped and composed of
ultrapure spherical silica, thereby minimizing the pos-
sibility of secondary interactions, a vast concern when
analyzing basic solutes.
A fundamental property of electrospray is in-solu-
tion ionization. BZE and COC are alkaloids with pka’s
of ’8.50 and at pH 4.0 are protonated. This rendered
both compounds amenable to the electrospray process.
At this low pH, interactions between activated silanol
groups and basic compounds are minimized. Further-
more, at acidic pH we observed less tailing of the
chromatographic peaks, and increased column perfor-
mance. The HPLC gradient conditions described pro-
duced extremely consistent retention of the analytes,
and provided adequate time to recondition the analyt-
ical system prior to the next injection.
The retention times of BZE, COC, and COC-d3 were
1.13, 1.15, and 1.15 min, respectively, yielding capacity
factors (k9) of 1.17, 1.21, and 1.21. Adjustments to
chromatographic parameters such as flowrate, column,
column temperature, and mobile phase composition could
have resulted in faster elution times. However, the
speed of analysis is tempered by the ability of the
detection system to acquire a number of data points to
sufficiently describe the chromatographic peaks. Our
chromatography generated extremely narrow peaks,
with an average peak width of around 3.6 s. Hence, it
was necessary to determine the MRM dwell time that
would generate a sufficient number of data points to
best describe the chromatographic peaks. Dwell-time
experiments were conducted for the nine transitions
monitored, with the optimum detected at 15 ms, repre-




MS/MS CID spectra and proposed fragmentation path-
ways of the protonated molecules for BZE, COC, and
COC-d3 are shown in Figure 1. Additional studies
utilizing the trideuterated cocaine analog, were per-
formed on a Finnigan LCQ ion trap mass spectrometer.
These analyses assisted in validating our proposed
mechanistic decomposition of CACM. Additionally,
Figure 4. (plus) ESI LC/MS MRM run of a blank urine sample and a 7.5 ng/mL benzoylecgonine
and cocaine cocktail standard, both fortified with 150 ng/mL cocaine-d3 internal standard and (c). (a)
and (b) are the MRM’s corresponding to benzoylecgonine and cocaine.
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these decompositions are in agreement with electron
ionization mechanisms previously described [17, 18],
and with work performed by Wang and Bartlett [19]. As
represented by the MSn spectra provided in Figure 2, it
is clear that dealkylation of COC-d3 produces the frag-
ment at m/z 185.1, and subsequentially CID of m/z 185.1
generates the trideuterated ecgonidine aldehyde moiety
at m/z 153.1.
The BZE CID spectrum shows an initial loss of the
elements of H2O to give the fragment at m/z 272.0. The
Ecgonidine methyl ester, ecgonidine aldehyde, and
benzaldehyde moieties are represented by the frag-
ments at m/z 168.2, 150.0 and 105.0. Additionally, the
fragment at m/z 82.2 likely represents cleavage of the
tropane ring to form the protonated methylpyrrole
structure. Apart from the mass shift due to the trideu-
terated species, the COC and COC-d3 CID spectra are
identical. A minor fragment is located at m/z 272.0 and
275.2, resulting from a loss of –CH3OH. Further decom-
position includes a loss of benzoic acid to give the
ecgonidine methyl ester and ecgonidine methyl ester-d3
moieties at m/z 182.0 and 185.0. Inductive cleavage of
ecgonidine methyl ester generates the ions at m/z 150.0
and 153.0, respectively. A proposed mechanism for this
decomposition is shown in Figure 3. Finally, the frag-
ments at m/z 82.2 and 85.0 are consistent with cleavage
of the bicyclic ring to form the protonated methylpyr-
role structure.
Assay selectivity was confirmed by the absence of
interfering peaks at the retention times for BZE, COC,
and COC-d3 in a blank human urine specimen. The
specific MRM transition, retention time, and base peak
normalized area abundance of the two qualifying tran-
sitions (BZE–40% and 41%, COC and COC-d3–22% and
22%, respectively), monitored were used to identify the
analytes. CACM standard MRM ion chromatograms for
a blank urine specimen and 7.5 ng/mL standard are
depicted in Figure 4. These MRM’s represent the quan-
titation transitions described earlier. Although not illus-
trated here, qualifying transitions were monitored for
each analyte. We wished to emulate as closely as
possible, the QC requirements promulgated by the
Federal Department of Health and Human Services,
Mandatory Guidelines for Federal Workplace Drug
Testing Programs [20], which require three descriptor
ions for selected ion monitoring by conventional mass
spectrometry. All qualifying transitions monitored
agreed with HHS guidelines of 620% normalized area
abundance’s relative to the quantitative transition [20].
However, in monitoring these transitions the ultimate
sensitivity may have been compromised, because of
sharing analysis time among several ions. Because
MS/MS provides an additional level of selectivity over
conventional mass spectrometry, we will conduct fu-
ture analyses without qualifier ions for CACM.
Method Validation
Linearity. The peak area ratios of the calibration stan-
dards were proportional to the analyte concentrations
in each assay over the nominal concentration range of
7.5 to 1000 ng/mL in the matrix. Linear fits were
employed to describe the calibration curves. Correlation
coefficients of greater than 0.9982 for BZE and COC
were obtained for the relationship between MRM ion
abundance ratio (analyte/internal standard) and the
corresponding calibration concentrations.
Accuracy and Precision. Intrarun accuracy and preci-
sion for triplicate urine standards, at each of seven
different concentrations were measured. The overall
mean interrun accuracy was 107% for both BZE and
COC. Interrun precision and accuracy data for these
standards are presented in Table 1.
Additionally, Table 1 summarizes the both the intra-
run accuracy and precision for the BZE and COC human
urine quality control specimens. The mean interrun pre-
cision was 2.5% for both BZE and COC. The overall mean
interrun accuracy was 103% for BZE and 105% for COC.
Table 1. (A) Human urine standards and (B) human urine quality control samples
Benzoylecgonine (N 5 3) Cocaine (N 5 3)
Mean (ng/mL) %CVa %MAb Mean (ng/mL) %CVa %MAb
(A) Standard (ng/mL)
7.5 7.1 1.1 95 7.7 5.9 100
15 13 7.6 87 19 7.8 130
30 34 5.9 110 33 8.4 110
75 71 5.4 95 73 5.6 97
150 160 5.9 110 150 3.9 100
500 450 3.5 90 500 1.7 100
1000 920 4.8 92 1110 1.9 110
(B) Spiked conc. (ng/mL)
30 33 1.9 110 30 2.4 100
150 160 2.7 110 160 2.0 110
1000 880 3.0 88 1060 3.0 106
a%CV 5 percent coefficient of variation for individual urine standard, quality control determined over three days.
b%MA 5 percent mean accuracy determined for individual urine standard, quality control determined over three days.
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System repeatability. The system repeatability, given as
%CV of mean peak-area ratios, was assessed using 100
of fortified “pooled” urine specimens at the HHS cutoff
concentration for positive identification, 150 ng/mL
[20]. Batch analyses were performed over the course of
five days, rendering %CV’s for BZE and COC of 0.62
and 6.9, respectively. System repeatability is shown in
Figure 5 for both compounds.
Limits of quantitation and detection. The lower limit of
detection (LOD) was defined as the lowest concentra-
tion of the calibration standards fortified in human
urine yielding a signal-to-noise ratio of at least 3.0. The
limit of quantitation (LOQ) was defined as the lowest
concentration of the calibration standards fortified in
human urine with a precision of 620%. The limit of
detection for both compounds was >2.5 ng/mL. The
LOQ’s for benzoylecgonine and cocaine were >3.0
ng/mL in human urine with total coefficients of varia-
tion less than 17%. It should be noted that analyte
enrichment and signal enhancement techniques were
not attempted. If performed, detection and quantitation
limits could have been extended to lower levels. These
data suggest that a qualitative and quantitative assess-
ment of CACM in human urine can be made with
satisfactory assurance.
Conclusion
A liquid chromatographic tandem mass spectrometric
method for the confirmation and quantitation of BZE
and COC in human urine has been developed. This
method is sensitive and selective for the target analytes
in a human urine matrix. The nominal limit of detection
for both analytes was >2.5 ng/mL for a 1.0-mL sample
size, and false positives were not observed. Specimen
preparation was held to a minimum, consisting solely
of an initial filtration step. This method may be suitable
for the routine confirmation of immunoassay COC-
positive samples at concentrations in humans from 3.0
to 1000 ng/mL. Future studies will investigate the
applicability of this method for specimens derived from
a “drug-abuse” population.
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Figure 5. Continuous analysis for 150 injections of human urine
specimens containing 150 ng/mL of CACM over a period of five
days. Internal standard calibration procedures were employed,
rendering CV’s for benzoylecgonine and cocaine of 2.5.
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